Braverman I M, Yager N B, Chen M, Cadman E C, Hait W N, Maynard T
J Am Acad Dermatol. 1987 Jan;16(1 Pt 1):45-60. doi: 10.1016/s0190-9622(87)70004-8.
Since 1979 a protocol of total body electron beam therapy (3,600 rads; 6 MeV), followed by six monthly cycles of chemotherapy (doxorubicin, 30 mg/M2 given intravenously once monthly, and cyclophosphamide, 100 mg/M2 given orally each day for 14 days), has been used to treat fifty patients with mycosis fungoides (primarily Stages I and II). A group of twenty-four patients, treated by identical high-dose electron beam therapy alone, served as control subjects. Actuarial analysis by the Kaplan-Meier method and statistical analysis by the generalized Wilcoxon test of Gehan demonstrated a significant difference (p = 0.008) in the probability of Stages I and II patients' remaining in complete clinical remission when combination therapy was compared with high-dose electron beam therapy alone. No statistically significant difference was demonstrated in patients in Stages III and IV mycosis fungoides. Although 60% of patients were in "complete clinical remission," the longest follow-up being 75 months, all continued to show karyotypic abnormalities of circulating lymphocytes, and 70% had intermittently and abnormally elevated blood levels of Sézary cells.
自1979年起，采用全身电子束疗法方案（3600拉德；6兆电子伏特），随后进行六个疗程的化疗（每月一次静脉注射阿霉素30毫克/平方米，环磷酰胺100毫克/平方米，每天口服，共14天），用于治疗50例蕈样肉芽肿患者（主要为I期和II期）。一组24例仅接受相同高剂量电子束疗法治疗的患者作为对照。采用Kaplan-Meier方法进行精算分析，通过Gehan广义Wilcoxon检验进行统计分析，结果表明，将联合治疗与单纯高剂量电子束疗法相比较时，I期和II期患者保持完全临床缓解的概率存在显著差异（p = 0.008）。在III期和IV期蕈样肉芽肿患者中未显示出统计学上的显著差异。尽管60%的患者处于“完全临床缓解”状态，最长随访时间为75个月，但所有患者的循环淋巴细胞仍持续显示核型异常，70%的患者血液中Sezary细胞水平间歇性异常升高。
